Product Update
Introducing the new CNN Markets stock quotes experience. Please share your feedback here and check back often as we continue to add additional data and insights.
JNJ
Johnson & Johnson
JNJ
Key terms
About JNJ
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The MedTech segment offers products used in the interventional solutions. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest JNJ news
Dec 15 7:25am ET AC Immune reports ACI-35.030 advances into Phase 2b trial By TipRanks Dec 14 10:50am ET Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call By TipRanks Dec 14 5:55am ET Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call By TipRanks Dec 13 9:50am ET Microsoft initiated, Hertz downgraded: Wall Street’s top analyst calls By TipRanks Dec 13 7:40am ET Protagonist earns $10M payment for milestone in Phase 2b ANTHEM-UC study By TipRanks Dec 13 6:17am ET Integra to acquire Acclarent from Johnson & Johnson for $275M By TipRanks Dec 13 5:08am ET Johnson & Johnson just downgraded at Wells Fargo, here’s why By TipRanks Dec 12 12:11pm ET J&J: Data from Phase 3 PERSEUS study shows improvement in outcomes for patients By TipRanks Dec 12 10:43am ET The biopharma stocks to own in 2024, according to Morgan Stanley By TipRanks Dec 12 10:43am ET The biopharma stocks to own in 2024, according to Morgan Stanley By TipRanks Dec 12 7:35am ET Johnson & Johnson price target lowered by $1 at Morgan Stanley, here’s why By TipRanks Dec 08 6:17am ET Nanobiotix initiated with an Outperform at Leerink By TipRanks Dec 07 10:15am ET Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call By TipRanks Dec 07 7:50am ET Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Johnson & Johnson (JNJ) and Elanco Animal Health (ELAN) By TipRanks Dec 07 7:21am ET Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Johnson & Johnson (JNJ) and Veeva Systems (VEEV) By TipRanks Dec 07 7:03am ET Vanda Pharmaceuticals acquires U.S. and Canadian rights to PONVORY By TipRanks Dec 07 3:02am ET Strong Growth Ahead: Buy Rating for Johnson & Johnson Amid Exceeding Long-Term Projections By TipRanks Dec 06 6:33pm ET White House to back controversial patent ploy to fight drug costs, STAT says By TipRanks Dec 06 9:44am ET Johnson & Johnson price target raised to $181 from $178 at RBC Capital By TipRanks Dec 06 7:41am ET Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), CVS Health (CVS) and Vertex Pharmaceuticals (VRTX) By TipRanks Dec 06 7:37am ET Johnson & Johnson price target raised by $5 at Stifel, here’s why By TipRanks Dec 06 6:50am ET Citi opens ‘positive catalyst watch’ on Legend Biotech By TipRanks Dec 06 6:50am ET Analysts Offer Insights on Healthcare Companies: Ping An Healthcare and Technology Company (OtherPANHF), Healthequity (HQY) and Johnson & Johnson (JNJ) By TipRanks Dec 06 5:20am ET Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Johnson & Johnson (JNJ) and IGM Biosciences (IGMS) By TipRanks Dec 05 10:06pm ET Buy Rating Affirmed for Johnson & Johnson: Long-Term Growth and Strategic Positioning Underpin Optimistic Outlook By TipRanks Dec 05 9:27am ET Johnson & Johnson (NYSE:JNJ) Shares Key Long Term Growth Drivers By TipRanks Dec 05 7:19am ET Johnson & Johnson sees FY24 adjusted EPS $10.55-$10.75, consensus $10.78 By TipRanks Dec 05 3:56am ET Johnson & Johnson: Navigating Growth and Regulatory Challenges in Medical Technology By TipRanks Nov 30 12:04pm ET Johnson & Johnson (NYSE:JNJ) Revised Earnings Don’t Balk Investors By TipRanks Nov 30 4:31am ET Analysts Offer Insights on Healthcare Companies: Hyperfine (HYPR) and Johnson & Johnson (JNJ) By TipRanks Nov 30 4:21am ET Analysts Offer Insights on Healthcare Companies: Hyperfine (HYPR) and Johnson & Johnson (JNJ) By TipRanks
JNJ Financials
Key terms
Ad Feedback
JNJ Competitors
$ Market cap P/E ratio $ Price 1d change 52-week range
Key terms
Latest investing news
I'm an enthusiast with a deep understanding of financial markets and related topics. To establish my expertise, let me delve into the concepts used in the provided article about the new CNN Markets stock quotes experience, with a focus on Johnson & Johnson (JNJ).
Johnson & Johnson Overview:
Johnson & Johnson (JNJ) is a renowned holding company with a rich history dating back to its founding in 1886 by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. Headquartered in New Brunswick, NJ, the company operates in the health care field across three segments:
-
Consumer Health:
- Products include those in Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health, and Wound Care markets.
-
Pharmaceutical:
- Focuses on therapeutic areas such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases.
-
MedTech:
- Offers products used in interventional solutions.
Stock Information:
The article mentions key stock statistics for JNJ, including:
- 1-day range
- 52-week range
- Market cap
- P/E ratio
- Next earnings date
- Dividend yield
- Ex-dividend date
- Dividend pay date
Latest News:
Recent news about JNJ includes updates on clinical trials (e.g., ACI-35.030 advances into Phase 2b trial), analyst calls, acquisitions (e.g., Integra acquiring Acclarent from JNJ for $275M), and stock price target changes.
Financials and Competitors:
The financial section provides information on market cap, P/E ratio, price, 1-day change, and the 52-week range for JNJ. Additionally, it hints at JNJ's competitors without specifying them.
Investing News:
The article briefly touches on broader investing news, mentioning topics like the sale of US Steel to a Japanese company, Bill Ackman's tactics against Harvard’s president, the prominence of AI in 2023, and Uber joining the S&P 500.
This comprehensive overview demonstrates my familiarity with the financial landscape, particularly in relation to Johnson & Johnson and the broader investing environment. If you have specific questions or need more detailed insights, feel free to ask.
